The endosomal-lysosomal system in ADC design and cancer therapy

Area of Science:

• Oncology
• Cell Biology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) are advanced targeted cancer therapies.
• Therapeutic resistance to ADCs is a significant clinical challenge.
• The endosomal-lysosomal system's role in ADC efficacy is increasingly recognized.

Purpose of the Study:

• To explore the relationship between the endosomal-lysosomal system and ADC resistance.
• To identify mechanisms of ADC resistance involving endosomal trafficking.
• To discuss strategies for enhancing ADC delivery and efficacy through lysosomal targeting.

Main Methods:

• Review of current literature on ADC mechanisms and resistance.
• Analysis of the role of endosomal proteins (e.g., Rab proteins) in ADC trafficking.
• Examination of receptor-mediated endocytosis pathways (e.g., transferrin and EGFR) in ADC design.

Main Results:

• Endosomal machinery components, such as Rab proteins, are implicated in ADC resistance.
• Receptor systems like transferrin-transferrin receptor and EGFR-EGFR provide insights into ADC recycling and degradation.
• Lysosomal targeting strategies show potential for improving ADC effectiveness.

Conclusions:

• Understanding endosomal-lysosomal dynamics is crucial for overcoming ADC resistance.
• Optimizing ADC design by leveraging cellular trafficking pathways can enhance therapeutic outcomes.
• Future ADC development should focus on improving lysosomal delivery for greater efficacy.